Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia
Clinical Transplantation · 2024
DOI: 10.1111/ctr.15325 ↗At a glance
Journal article in Clinical Transplantation, 2024. Written by Sarah Khan and 6 co-authors. Institution: Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA. Major MEDLINE topics: Lung Transplantation, Graft Survival, Postoperative Complications, Hepatitis C. Cited 7 times so far (Crossref); 20 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Background/aims Direct‐acting antiviral (DAA) therapy has revolutionized solid organ transplantation by providing an opportunity to utilize organs from HCV‐viremic donors. Though transplantation of HCV‐viremic donor organs into aviremic recipients is safe in the short term, midterm data on survival and post‐transplant complications is lacking. We provide a midterm assessment of complications of lung transplantation (LT) up to 2 years post‐transplant, including patient and graft survival between HCV‐viremic transplantation (D+) and HCV‐aviremic transplantation (D‐).
Methods
This is a retrospective cohort study including 500 patients from 2018 to 2022 who underwent LT at our quaternary care institution. Outcomes of patients receiving D+ grafts were compared to those receiving D‐ grafts. Recipients of HCV antibody+ but PCR‐ grafts were treated as D‐ recipients.
Results
We identified 470 D‐ and 30 D+ patients meeting inclusion criteria. Crude mortality did not differ between groups ( p = .43). Patient survival at years 1 and 2 did not differ between D+ and D‐ patients ( p = .89, p = .87, respectively), and graft survival at years 1 and 2 did not differ between the two groups ( p = .90, p = .88, respectively). No extrahepatic manifestations or fibrosing cholestatic hepatitis (FCH) occurred among D+ recipients. D+ and D‐ patients had similar rates of post‐transplant chronic lung allograft rejection (CLAD) ( p = 6.7% vs. 12.8%, p = .3), acute cellular rejection (60.0% vs. 58.0%, p = .8) and antibody‐mediated rejection (16.7% vs. 14.2%, p = .7).
Conclusion
There is no difference in midterm patient or graft survival between D+ and D‐LT. No extrahepatic manifestations of HCV occurred. No differences in any type of rejection including CLAD were observed, though follow‐up for CLAD was limited. These results provide additional support for the use of HCV‐viremic organs in selected recipients in LT.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Internal Medicine, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio, USA.
- Department of Gastroenterology, Hepatology, and Nutrition, Cleveland Clinic, Cleveland, Ohio, USA.
- Respiratory Institute, Cleveland Clinic, Cleveland, Ohio, USA.
ORCID profiles: Sarah Khan
Cite
APA
Khan, S., Mazumder, R., Wang, X., Wang, Y., Sims, O. T., Budev, M., & Carey, W. (2024). Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia. Clinical Transplantation. https://doi.org/10.1111/ctr.15325
Vancouver
Khan S, Mazumder R, Wang X, Wang Y, Sims OT, Budev M, et al. Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia. Clinical Transplantation. 2024. doi:10.1111/ctr.15325
BibTeX
@article{Khan2024,
author = {Khan, Sarah and Mazumder, Ritika and Wang, Xiaofeng and Wang, Yifan and Sims, Omar T and Budev, Marie and Carey, William},
title = {Hepatitis C viremic lung transplantation to aviremic recipients: Comprehensive outcomes and post‐transplant viremia},
journal = {Clinical Transplantation},
year = {2024},
doi = {10.1111/ctr.15325}
}
EUVIMED